Back

Latest Forum Topics / Riverstone    Last:0.885 --

Post Reply

Riverstone go go go! Post Reply Rate topic
Chansenghoe1971 Elite	01-Feb-2024 11:25        Chansenghoe1971 About Contact  Quote this Post!
x 0   x 0  Alert Admin	RS is the Best Better than the Rest.
Useful To Me  Not Useful To Me
msksmsks Supreme	01-Feb-2024 11:21        msksmsks About Contact  Quote this Post!
x 0   x 0  Alert Admin	Duriing these challenging and high interest rate environment,  how many Companies issue such Rosy profit guidance ? RS differentiates itself fm it' s peers all these while whom most of them still struggling yet it had emerged strongly with qtyly  profit and ushering special and higher dividend even pandemic is over. Such guidance by Mr Wong whom a low profile bizman yet always deliver is someone  that command respect . RS is net cash and zero debt.    I look fwd a good FY24 as guided by RS with higher dividend expectation  and  a strong rally of its share price Cheers
Useful To Me  Not Useful To Me
msksmsks Supreme	01-Feb-2024 10:46        msksmsks About Contact  Quote this Post!
x 0   x 0  Alert Admin	Mkt is fwd looking and this is what Mr Wong had mentioned during their FY23 Q3 result update: Quote: &ldquo We are upbeat about FY2024 with the expected recovery of cleanroom gloves driven by an improved consumer electronics sector. At the same time, we continue to see customer expansion opportunities for our customised range of products, Unquote: In this regard, wuld expect a higher revenue for FY24 and looking forward to higher dividend payout and perhaps a special dividend is always welcome Cheers
Useful To Me  Not Useful To Me
beng1102 Elite	01-Feb-2024 10:30        beng1102 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yes.  Strong buy now to position for a good profit soon. ETHunter      ( Date: 01-Feb-2024 09:58) Posted: Breaking 74c v soon before gap up. Results this month likely hit ATH.
Useful To Me  Not Useful To Me
msksmsks Supreme	01-Feb-2024 10:15        msksmsks About Contact  Quote this Post!
x 0   x 0  Alert Admin	Expecting a big CNY Angpow fm Mr Wong whom always  very generous in giving dividends to reward shareholders.
Useful To Me  Not Useful To Me
ETHunter Master	01-Feb-2024 09:58        ETHunter About Contact  Quote this Post! Style: Combined   Mood:
x 0   x 0  Alert Admin	Breaking 74c v soon before gap up. Results this month likely hit ATH.
Useful To Me  Not Useful To Me
beng1102 Elite	31-Jan-2024 21:06        beng1102 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Strong buy now as price has corrected and more likely to go up. msksmsks      ( Date: 31-Jan-2024 15:09) Posted: Accumulation gg on Expecting a good set of FY23 result and ushering generous dividend payout with no capex needed Recovery in tech sector this year agurs well for RS which share price maybe lifted higher by analysts
Useful To Me  Not Useful To Me
msksmsks Supreme	31-Jan-2024 15:09        msksmsks About Contact  Quote this Post!
x 0   x 0  Alert Admin	Accumulation gg on Expecting a good set of FY23 result and ushering generous dividend payout with no capex needed Recovery in tech sector this year agurs well for RS which share price maybe lifted higher by analysts
Useful To Me  Not Useful To Me
Sgvale Supreme	26-Jan-2024 13:12        Sgvale About Contact  Quote this Post!
x 0   x 0  Alert Admin	Lai lai
Useful To Me  Not Useful To Me
sweet639 Veteran	26-Jan-2024 12:35        sweet639 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Trading house always one step behind, why never ask to BUY when market was down so much yesterday? ETHunter      ( Date: 26-Jan-2024 11:18) Posted: UOB Kayhian report Riverstone&rsquo s cleanroom gloves, which contribute about 80% of earnings, are expected to see a recovery in demand, driven by new clients onboarded in the preceding year and improvement in the semiconductor industry in 2024. On the healthcare gloves front, sustained product customisation efforts with new production lines are yielding results, as seen from increased demand for higher-margin customised healthcare gloves. We upgrade Riverstone to BUY with a 22% higher target price of S$0.82. WHAT&rsquo S NEW &bull Recent 3Q23 results signal potential turnaround in 2024. Riverstone Holdings (Riverstone) reported a 3Q23 net profit of RM59.3m (+26.5% qoq, -6.6% yoy), with 9M23 net profit falling 43.9% yoy to RM152.9m. While the glove industry faced a slowdown from pandemic-induced oversupply and less-than-optimal utilisation in 2023, we note that 3Q23 gross profit margin improved 6ppt qoq and 1.1ppt yoy. This significant expansion was driven by a stronger product mix, with more customised healthcare gloves delivered, and lower raw material costs during the period. &bull 97% dividend payout ratio as of 9M23 shows a strong vote of confidence strong balance sheet enables higher payout ratio of above 100%, translating into an attractive dividend yield of 8.5% for 2024. Riverstone declared an interim dividend of 5.0 sen, taking total 9M23 dividends to 10.0 sen/share (9M22: 16.0 sen/share), implying a 97% dividend payout ratio. Given that Riverstone has a strong balance sheet with net cash balance of RM951m as of 9M23, which is equivalent to S$0.18/share (around 30% of market cap), a payout ratio above 100% is highly likely. &bull Benefitting from higher-margin customised healthcare gloves. Besides being the leading global supplier for cleanroom and healthcare gloves, Riverstone offers products such as finger cots, cleanroom packaging bags and face masks. With more than 30 years of expertise, Riverstone' s cleanroom products under own brand RS have a unique competitive advantage. As for its healthcare gloves, Riverstone is in the midst of demolishing its 10-yearold production lines to build newer lines for customised products. This has allowed it to expand its gross margin substantially, as customised gloves fetch approximately 30% gross profit margin, around six times that of generic gloves. Moving forward, increased demand for customised healthcare gloves will drive higher margins for Riverstone... Results coming. Sales and profits will be up. Dividend coming. TP also up.
Useful To Me  Not Useful To Me
ETHunter Master	26-Jan-2024 11:18        ETHunter About Contact  Quote this Post! Style: Combined   Mood:
x 0   x 0  Alert Admin	UOB Kayhian report Riverstone&rsquo s cleanroom gloves, which contribute about 80% of earnings, are expected to see a recovery in demand, driven by new clients onboarded in the preceding year and improvement in the semiconductor industry in 2024. On the healthcare gloves front, sustained product customisation efforts with new production lines are yielding results, as seen from increased demand for higher-margin customised healthcare gloves. We upgrade Riverstone to BUY with a 22% higher target price of S$0.82. WHAT&rsquo S NEW &bull Recent 3Q23 results signal potential turnaround in 2024. Riverstone Holdings (Riverstone) reported a 3Q23 net profit of RM59.3m (+26.5% qoq, -6.6% yoy), with 9M23 net profit falling 43.9% yoy to RM152.9m. While the glove industry faced a slowdown from pandemic-induced oversupply and less-than-optimal utilisation in 2023, we note that 3Q23 gross profit margin improved 6ppt qoq and 1.1ppt yoy. This significant expansion was driven by a stronger product mix, with more customised healthcare gloves delivered, and lower raw material costs during the period. &bull 97% dividend payout ratio as of 9M23 shows a strong vote of confidence strong balance sheet enables higher payout ratio of above 100%, translating into an attractive dividend yield of 8.5% for 2024. Riverstone declared an interim dividend of 5.0 sen, taking total 9M23 dividends to 10.0 sen/share (9M22: 16.0 sen/share), implying a 97% dividend payout ratio. Given that Riverstone has a strong balance sheet with net cash balance of RM951m as of 9M23, which is equivalent to S$0.18/share (around 30% of market cap), a payout ratio above 100% is highly likely. &bull Benefitting from higher-margin customised healthcare gloves. Besides being the leading global supplier for cleanroom and healthcare gloves, Riverstone offers products such as finger cots, cleanroom packaging bags and face masks. With more than 30 years of expertise, Riverstone' s cleanroom products under own brand RS have a unique competitive advantage. As for its healthcare gloves, Riverstone is in the midst of demolishing its 10-yearold production lines to build newer lines for customised products. This has allowed it to expand its gross margin substantially, as customised gloves fetch approximately 30% gross profit margin, around six times that of generic gloves. Moving forward, increased demand for customised healthcare gloves will drive higher margins for Riverstone... Results coming. Sales and profits will be up. Dividend coming. TP also up.
Useful To Me  Not Useful To Me
msksmsks Supreme	26-Jan-2024 10:54        msksmsks About Contact  Quote this Post!
x 0   x 0  Alert Admin	ICHIBAN,
Useful To Me  Not Useful To Me
ETHunter Master	25-Jan-2024 11:19        ETHunter About Contact  Quote this Post! Style: Combined   Mood:
x 0   x 0  Alert Admin	RS likely to break previous high or 74c and hit 80c soon. Coming results will be the catalyts..   Traveler      ( Date: 22-Jan-2024 09:54) Posted: Last week shot sell quantity was about 2 million shares. Guess will start to cover ? Huataarrhh      ( Date: 22-Jan-2024 09:23) Posted: CIMB report  4Q23F preview: improving profitability, special dividend likely We project Riverstone (RSTON) to record a net profit of RM62m for 4Q23F (+5% qoq, +48% yoy), helped by a recovery in glove demand at end-2023F. We estimate RSTON$Bc`QT(B cleanroom segment volume grew 5% qoq in 4Q23F, while its healthcare segment GPM improved to 19% in 4Q23F (3Q23: 16%) as RSTON$Bc`QT(B strategy to focus on customised glove paid off. Overall, we project RSTON$Bc`QT(B FY23F net profit at RM215m, 65% above its pre-pandemic (FY19) level. We also see likelihood of a special dividend being declared as RSTON seeks to return excess cash to shareholders (end-Sep: net cash of RM950m). Our current FY23F DPS of 15sen assumes a 100% payout ratio (FY22: 160%).   Cleanroom glove volumes to recover RSTON sees further volume recovery in FY24F, riding on the modest recovery of the electronics manufacturing sector. RSTON is currently in talks with customers on a possible slight price reduction in return for price-locking. However, it is confident segment margins can be kept at c.50% as selling prices are still at a c.30% premium to pre-Covid levels.   Strategy to focus on customised gloves pays off We expect RSTON to see stronger healthcare segment ASP and GPM in FY24F via its emphasis on growing its customised glove offerings. Catered to laboratory use or corrosion-resistant applications, such products can command GPM of up to c.30% (compared to < 5% for generic gloves). RSTON said there is currently limited competition in this niche market, and it has been able to capture this opportunity as its dipping lines were designed to cater to more flexible manufacturing originally intended for cleanroom glove production. RSTON is currently reconfiguring one of its plants (previously decommissioned) to cater to the production of customised gloves and expects the new capacity to come onstream from 2Q24F onwards.   Reiterate Add with a higher TP of S$0.88 Reiterate Add as we believe 4Q23F marks a fundamental inflection point with RSTON$Bc`QT(B net profit returning to yoy growth. We think RSTON can emerge stronger from the industry downcycle vs. peers with its nimble execution, as it prioritises higher-margin customised products and has unique cleanroom offerings. Our TP is raised to S$0.88, now based on 16x CY25F P/E (RSTON$Bc`QT(B 5-year pre-Covid historical mean), from 14.5x (1 s.d. above) previously. Re-rating catalysts include higher dividend payout and stronger demand recovery as distributors$Bc`!& (Binventory levels normalise. Downside risks include slower-than-expected cleanroom demand recovery and intensifying price competition hurting margins.
Useful To Me  Not Useful To Me
ETHunter Master	25-Jan-2024 10:03        ETHunter About Contact  Quote this Post! Style: Combined   Mood:
x 0   x 0  Alert Admin	RS report earnings next few weeks. Should see stock up with such strong results forecast.
Useful To Me  Not Useful To Me
Traveler Member	22-Jan-2024 09:54        Traveler About Contact  Quote this Post!
x 0   x 0  Alert Admin	Last week shot sell quantity was about 2 million shares. Guess will start to cover ? Huataarrhh      ( Date: 22-Jan-2024 09:23) Posted: CIMB report  4Q23F preview: improving profitability, special dividend likely We project Riverstone (RSTON) to record a net profit of RM62m for 4Q23F (+5% qoq, +48% yoy), helped by a recovery in glove demand at end-2023F. We estimate RSTON$Bc`QT(B cleanroom segment volume grew 5% qoq in 4Q23F, while its healthcare segment GPM improved to 19% in 4Q23F (3Q23: 16%) as RSTON$Bc`QT(B strategy to focus on customised glove paid off. Overall, we project RSTON$Bc`QT(B FY23F net profit at RM215m, 65% above its pre-pandemic (FY19) level. We also see likelihood of a special dividend being declared as RSTON seeks to return excess cash to shareholders (end-Sep: net cash of RM950m). Our current FY23F DPS of 15sen assumes a 100% payout ratio (FY22: 160%).   Cleanroom glove volumes to recover RSTON sees further volume recovery in FY24F, riding on the modest recovery of the electronics manufacturing sector. RSTON is currently in talks with customers on a possible slight price reduction in return for price-locking. However, it is confident segment margins can be kept at c.50% as selling prices are still at a c.30% premium to pre-Covid levels.   Strategy to focus on customised gloves pays off We expect RSTON to see stronger healthcare segment ASP and GPM in FY24F via its emphasis on growing its customised glove offerings. Catered to laboratory use or corrosion-resistant applications, such products can command GPM of up to c.30% (compared to < 5% for generic gloves). RSTON said there is currently limited competition in this niche market, and it has been able to capture this opportunity as its dipping lines were designed to cater to more flexible manufacturing originally intended for cleanroom glove production. RSTON is currently reconfiguring one of its plants (previously decommissioned) to cater to the production of customised gloves and expects the new capacity to come onstream from 2Q24F onwards.   Reiterate Add with a higher TP of S$0.88 Reiterate Add as we believe 4Q23F marks a fundamental inflection point with RSTON$Bc`QT(B net profit returning to yoy growth. We think RSTON can emerge stronger from the industry downcycle vs. peers with its nimble execution, as it prioritises higher-margin customised products and has unique cleanroom offerings. Our TP is raised to S$0.88, now based on 16x CY25F P/E (RSTON$Bc`QT(B 5-year pre-Covid historical mean), from 14.5x (1 s.d. above) previously. Re-rating catalysts include higher dividend payout and stronger demand recovery as distributors$Bc`!& (Binventory levels normalise. Downside risks include slower-than-expected cleanroom demand recovery and intensifying price competition hurting margins.
Useful To Me  Not Useful To Me
Huataarrhh Senior	22-Jan-2024 09:23        Huataarrhh About Contact  Quote this Post!
x 0   x 0  Alert Admin	CIMB report  4Q23F preview: improving profitability, special dividend likely We project Riverstone (RSTON) to record a net profit of RM62m for 4Q23F (+5% qoq, +48% yoy), helped by a recovery in glove demand at end-2023F. We estimate RSTON$Bc`QT(B cleanroom segment volume grew 5% qoq in 4Q23F, while its healthcare segment GPM improved to 19% in 4Q23F (3Q23: 16%) as RSTON$Bc`QT(B strategy to focus on customised glove paid off. Overall, we project RSTON$Bc`QT(B FY23F net profit at RM215m, 65% above its pre-pandemic (FY19) level. We also see likelihood of a special dividend being declared as RSTON seeks to return excess cash to shareholders (end-Sep: net cash of RM950m). Our current FY23F DPS of 15sen assumes a 100% payout ratio (FY22: 160%).   Cleanroom glove volumes to recover RSTON sees further volume recovery in FY24F, riding on the modest recovery of the electronics manufacturing sector. RSTON is currently in talks with customers on a possible slight price reduction in return for price-locking. However, it is confident segment margins can be kept at c.50% as selling prices are still at a c.30% premium to pre-Covid levels.   Strategy to focus on customised gloves pays off We expect RSTON to see stronger healthcare segment ASP and GPM in FY24F via its emphasis on growing its customised glove offerings. Catered to laboratory use or corrosion-resistant applications, such products can command GPM of up to c.30% (compared to < 5% for generic gloves). RSTON said there is currently limited competition in this niche market, and it has been able to capture this opportunity as its dipping lines were designed to cater to more flexible manufacturing originally intended for cleanroom glove production. RSTON is currently reconfiguring one of its plants (previously decommissioned) to cater to the production of customised gloves and expects the new capacity to come onstream from 2Q24F onwards.   Reiterate Add with a higher TP of S$0.88 Reiterate Add as we believe 4Q23F marks a fundamental inflection point with RSTON$Bc`QT(B net profit returning to yoy growth. We think RSTON can emerge stronger from the industry downcycle vs. peers with its nimble execution, as it prioritises higher-margin customised products and has unique cleanroom offerings. Our TP is raised to S$0.88, now based on 16x CY25F P/E (RSTON$Bc`QT(B 5-year pre-Covid historical mean), from 14.5x (1 s.d. above) previously. Re-rating catalysts include higher dividend payout and stronger demand recovery as distributors$Bc`!& (Binventory levels normalise. Downside risks include slower-than-expected cleanroom demand recovery and intensifying price competition hurting margins.
Useful To Me  Not Useful To Me
FreedomAngelz Veteran	18-Jan-2024 13:59        FreedomAngelz About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hope it drop more so that i can scoop up at a low price. Sold some at 0.715, hoping to buy back at 0.615
Useful To Me  Not Useful To Me
Tracer63 Elite	18-Jan-2024 13:19        Tracer63 About Contact  Quote this Post!
x 0   x 0  Alert Admin	0.64 critical support, hopes it rebounds from here
Useful To Me  Not Useful To Me
Chansenghoe1971 Elite	17-Jan-2024 22:12        Chansenghoe1971 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yes Though I am not a shh, this is the real deal amongst ppe, the rest such as UG Top glove what not are all junk stocks. I am sure RS will bounce back but I think the support is 60. Tob231      ( Date: 17-Jan-2024 22:03) Posted: the market will likely turn bullish and volatility will likely move back toward the mean. Steady steady 😀
Useful To Me  Not Useful To Me
Tob231 Elite	17-Jan-2024 22:03        Tob231 About Contact  Quote this Post!
x 0   x 0  Alert Admin	the market will likely turn bullish and volatility will likely move back toward the mean. Steady steady 😀
Useful To Me  Not Useful To Me

                                                         First   < Newer   2301-2320 of 3892   Older>   Last